While targeting of OSE using the Amhr2-Cre transgenic to activate KrasG12D and to inactivate Pten resulted in low grade serous adenocarcinomas[51], similar activation/inactivation of these genes induced following the intrabursal injection of Ad-CMV-Cre led to the development of ovarian endometrioid adenocarcinomas[76]. This evidence concerns the gene PTEN and ovarian endometrioid adenocarcinoma.